Ries, M.; Moulari, B.; Shetab Boushehri, M.A.; Ali, M.E.; Molnar, D.; Béduneau, A.; Pellequer, Y.; Lamprecht, A.
Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting. Pharmaceutics 2022, 14, 352.
https://doi.org/10.3390/pharmaceutics14020352
AMA Style
Ries M, Moulari B, Shetab Boushehri MA, Ali ME, Molnar D, Béduneau A, Pellequer Y, Lamprecht A.
Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting. Pharmaceutics. 2022; 14(2):352.
https://doi.org/10.3390/pharmaceutics14020352
Chicago/Turabian Style
Ries, Markus, Brice Moulari, Maryam A. Shetab Boushehri, Mohamed Ehab Ali, Daniel Molnar, Arnaud Béduneau, Yann Pellequer, and Alf Lamprecht.
2022. "Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting" Pharmaceutics 14, no. 2: 352.
https://doi.org/10.3390/pharmaceutics14020352
APA Style
Ries, M., Moulari, B., Shetab Boushehri, M. A., Ali, M. E., Molnar, D., Béduneau, A., Pellequer, Y., & Lamprecht, A.
(2022). Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting. Pharmaceutics, 14(2), 352.
https://doi.org/10.3390/pharmaceutics14020352